Health Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Agendia Bv

Agendia's Breast Cancer Test MammaPrint Identifies New Subset of Low Risk HER2+ Patients

announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

HER2+ patients are commonly identified as high risk, yet MammaPrint was able to identify a low risk subgroup of HER2+ patients, who subsequently experienced a 10 year disease-free survival of close to 90 percent even in the absence of (neo)adjuvant trastuzumab (Herceptin(R)) and chemotherapy. Additionally, in a subgroup of highly...

• View Other Issues of Health Business Week
  
• View Other NewsRx Publications